Logo image of ENGN

ENGENE HOLDINGS INC (ENGN) Stock Fundamental Analysis

USA - NASDAQ:ENGN - CA29286M1059 - Common Stock

8.14 USD
+0.54 (+7.11%)
Last: 10/2/2025, 8:00:02 PM
Fundamental Rating

2

Overall ENGN gets a fundamental rating of 2 out of 10. We evaluated ENGN against 536 industry peers in the Biotechnology industry. ENGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ENGN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ENGN has reported negative net income.
ENGN had a negative operating cash flow in the past year.
In the past 5 years ENGN reported 4 times negative net income.
In the past 5 years ENGN always reported negative operating cash flow.
ENGN Yearly Net Income VS EBIT VS OCF VS FCFENGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

ENGN's Return On Assets of -38.58% is fine compared to the rest of the industry. ENGN outperforms 60.63% of its industry peers.
ENGN has a Return On Equity of -47.20%. This is in the better half of the industry: ENGN outperforms 67.16% of its industry peers.
Industry RankSector Rank
ROA -38.58%
ROE -47.2%
ROIC N/A
ROA(3y)-5.96%
ROA(5y)N/A
ROE(3y)-6.79%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENGN Yearly ROA, ROE, ROICENGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ENGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENGN Yearly Profit, Operating, Gross MarginsENGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

ENGN has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ENGN has a worse debt to assets ratio.
ENGN Yearly Shares OutstandingENGN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M 50M
ENGN Yearly Total Debt VS Total AssetsENGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 2.86 indicates that ENGN is not a great score, but indicates only limited risk for bankruptcy at the moment.
ENGN has a better Altman-Z score (2.86) than 69.78% of its industry peers.
ENGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
ENGN has a Debt to Equity ratio of 0.09. This is in the lower half of the industry: ENGN underperforms 63.06% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 2.86
ROIC/WACCN/A
WACCN/A
ENGN Yearly LT Debt VS Equity VS FCFENGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

ENGN has a Current Ratio of 10.34. This indicates that ENGN is financially healthy and has no problem in meeting its short term obligations.
ENGN's Current ratio of 10.34 is amongst the best of the industry. ENGN outperforms 82.28% of its industry peers.
A Quick Ratio of 10.34 indicates that ENGN has no problem at all paying its short term obligations.
ENGN has a Quick ratio of 10.34. This is amongst the best in the industry. ENGN outperforms 82.28% of its industry peers.
Industry RankSector Rank
Current Ratio 10.34
Quick Ratio 10.34
ENGN Yearly Current Assets VS Current LiabilitesENGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

ENGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -69.41%.
EPS 1Y (TTM)-69.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-78.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ENGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.63% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-50.26%
EPS Next 2Y-29.2%
EPS Next 3Y-8.89%
EPS Next 5Y18.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENGN Yearly Revenue VS EstimatesENGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ENGN Yearly EPS VS EstimatesENGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENGN. In the last year negative earnings were reported.
Also next year ENGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENGN Price Earnings VS Forward Price EarningsENGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENGN Per share dataENGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

ENGN's earnings are expected to decrease with -8.89% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.2%
EPS Next 3Y-8.89%

More info and screens

0

5. Dividend

5.1 Amount

ENGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENGENE HOLDINGS INC

NASDAQ:ENGN (10/2/2025, 8:00:02 PM)

8.14

+0.54 (+7.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-11 2025-09-11/amc
Earnings (Next)03-02 2026-03-02
Inst OwnersN/A
Inst Owner Change-1.25%
Ins OwnersN/A
Ins Owner Change0%
Market Cap416.04M
Analysts84.71
Price Target21.01 (158.11%)
Short Float %N/A
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.95%
Min EPS beat(2)-11.52%
Max EPS beat(2)-0.38%
EPS beat(4)1
Avg EPS beat(4)-6.73%
Min EPS beat(4)-26.76%
Max EPS beat(4)11.73%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.39%
PT rev (3m)-8.26%
EPS NQ rev (1m)-4.76%
EPS NQ rev (3m)-3.98%
EPS NY rev (1m)-6.82%
EPS NY rev (3m)-6.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.07
P/tB 2.07
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-2.41
Fwd EYN/A
FCF(TTM)-1.86
FCFYN/A
OCF(TTM)-1.84
OCFYN/A
SpS0
BVpS3.93
TBVpS3.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.58%
ROE -47.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-5.96%
ROA(5y)N/A
ROE(3y)-6.79%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 305.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.34
Quick Ratio 10.34
Altman-Z 2.86
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.46%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-78.12%
EPS Next Y-50.26%
EPS Next 2Y-29.2%
EPS Next 3Y-8.89%
EPS Next 5Y18.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-123.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-86.23%
EBIT Next 3Y-36.06%
EBIT Next 5Y14.43%
FCF growth 1Y-409.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-407.9%
OCF growth 3YN/A
OCF growth 5YN/A